News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? Over the last six months, Gilead Sciences's shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500's 13.1% gain. This might have investors contemplating their next …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%This article provides an in-depth AI-driven analysis for Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It details institutional trading strategies with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging. …
Gilead Sciences is partnering with Nucleai for AI-powered tissue analytics to enhance its antibody-drug conjugate (ADC) clinical development and precision oncology efforts. This collaboration supports Gilead's long-term strategy to pivot into oncology, leveraging its strong HIV core business. However, despite the potential of AI-enabled …
Summit Global Investments initiated a new position in Gilead Sciences, acquiring 11,712 shares valued at $1.48 million during the second quarter. Gilead Sciences reported strong Q2 earnings, surpassing revenue and EPS expectations, with a 10.6% year-over-year revenue increase and declared a quarterly dividend of …
Simplify Asset Management Inc. increased its stake in Thermo Fisher Scientific Inc. (TMO) by 32.6% in the second quarter, purchasing 5,670 additional shares. This brings their total holding to 23,079 shares, valued at approximately $11.6 million. Institutional investors collectively own 89.23% of TMO, with …
HM Payson & Co. reduced its stake in Thermo Fisher Scientific Inc. by 11.3%, selling 20,885 shares but still holding 163,790 shares valued at $82.1 million. Despite insider selling of over $30.6 million in the last 90 days, Thermo Fisher reported strong quarterly results …
Wedge Capital Management L L P NC significantly reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 93.3% in the second quarter, selling over 11,000 shares. Despite this, other institutional investors either increased or initiated stakes in the company, with institutional ownership remaining …
Centric Wealth Management has acquired a new stake of 26,506 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $3.52 million during the second quarter. This move is part of broader institutional interest, with 83.67% of Gilead's stock owned by institutional investors and hedge …
GSA Capital Partners LLP has acquired a new position in MSCI Inc. (NYSE:MSCI), purchasing 3,826 shares valued at approximately $2.143 million during the second quarter. This move comes as other institutional investors have also adjusted their stakes in the technology company. MSCI recently announced …
Quantinno Capital Management LP significantly increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 387.3% in the first quarter, acquiring an additional 36,144 shares. This brings their total holdings to 45,476 shares, valued at approximately $1.12 million. While institutional investors own a large portion …
Cornerstone Capital Inc. has acquired a new stake in Gilead Sciences, Inc., purchasing 36,158 shares valued at approximately $4.57 million during the second quarter. This move comes as institutional investors and hedge funds collectively own 83.67% of the company. Gilead recently reported stronger-than-expected quarterly …
Bank Hapoalim BM has invested $1.78 million in Edwards Lifesciences Corporation by purchasing 19,640 shares. This comes as other institutional investors have also adjusted their holdings in the medical research company. Analysts maintain a "Moderate Buy" rating for Edwards Lifesciences, with a consensus target …
Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Wenbin Jiang Chief Financial Officer - William McCombe Investor Relations - Mark Meehan Full Conference Call Transcript Operator: Hello, and thank you for standing …
Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …
This page provides financial information for the iShares MSCI Singapore ETF (BEWS39) on the B3 exchange. It includes an overview of its financials, with sections for statements, statistics, dividends, earnings, and segments, though specific data is not displayed. The article highlights that the market …
Strategy has criticized global index provider MSCI Inc. for its proposed plan to remove it from listings, arguing that neither Strategy nor Bitcoin requires MSCI for survival. MSCI's attempt to exclude "non-operating companies" that primarily hold crypto assets has been met with resistance from …
MSCI Inc. is consulting on new index rules to exclude "non-operating companies" that resemble investment funds, potentially impacting niche holdings like Bitcoin treasuries and uranium vehicles. While this move reinforces MSCI's index integrity and institutional appeal, it may also influence asset-based fee trajectories and …
Alto Neuroscience (ANRO) saw a 13.5% stock increase after expanding its ALTO-207 Phase 3 trial for treatment-resistant depression and securing approximately $100 million in new funding. Despite ongoing net losses, the company aims to validate its data-driven approach, with short-term focus on the expanded …
This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.
Search by ticker symbol or company name and select a result to open its chart.